相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer
Ayako Shiono et al.
CANCER MEDICINE (2023)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
Kyoichi Kaira et al.
MEDICINA-LITHUANIA (2021)
Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy
Hisao Imai et al.
ONCOLOGY (2021)
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
Nathalie Baize et al.
LANCET ONCOLOGY (2020)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors
Hisao Imai et al.
CHEMOTHERAPY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Current standards for clinical management of small cell lung cancer
Anna F. Farago et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Clinical significance of post-progression survival in lung cancer
Hisao Imai et al.
THORACIC CANCER (2017)
Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide
Hisao Imai et al.
CANADIAN RESPIRATORY JOURNAL (2016)
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer
Nathan R. Foster et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Small Cell Lung Cancer: Where Do We Go From Here?
Lauren Averett Byers et al.
CANCER (2015)
Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients
Matthew B. Schabath et al.
LUNG CANCER (2014)
Individual-level data on the relationships of progression-free survival, post-progression survival and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer
H. Imai et al.
NEOPLASMA (2014)
Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
H. Hayashi et al.
ANNALS OF ONCOLOGY (2012)
Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive Stage Small-Cell Lung Cancer Findings on the Basis of North Central Cancer Treatment Group Trials
Nathan R. Foster et al.
CANCER (2011)
Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
Katsuyuki Hotta et al.
PLOS ONE (2011)
Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
J. C. Soria et al.
ANNALS OF ONCOLOGY (2010)
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
I. K. Demedts et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Kristine R. Broglio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
A statistical model for the dependence between progression-free survival and overall survival
Frank Fleischer et al.
STATISTICS IN MEDICINE (2009)
Performance Status and Sensitivity to First-line Chemotherapy Are Significant Prognostic Factors in Patients With Recurrent Small Cell Lung Cancer Receiving Second-line Chemotherapy
Young Hak Kim et al.
CANCER (2008)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Statistical evaluation of biomarkers as surrogate endpoints: a literature review
CJ Weir et al.
STATISTICS IN MEDICINE (2006)
Basic treatment considerations using chemotherapy for patients with small cell lung cancer
BE Johnson et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2004)
分享论文
